Dr Samanta Cimitan, CEO of Celonic Group and Dr Horst Lindhofer, CEO of LINDIS Biotech
Celonic Group, a biologics contract development and manufacturing organization (CDMO), has announced the signing of a multi-year commercial manufacturing agreement with LINDIS Biotech for the production of catumaxomab for commercial supply.
Catumaxomab is a first-in-class, trifunctional bispecific monoclonal antibody designed for the intraperitoneal treatment of malignant ascites in adults with epithelial cell adhesion molecule (EpCAM)-positive carcinomas who are not eligible for other systemic anticancer therapy. Malignant ascites is an abnormal accumulation of fluid in the peritoneal cavity that commonly arises from advanced-stage cancers.
Catumaxomab effectively destroys cancer cells by attaching to two antigens: EpCAM and CD3 to form a bridge between the cancer cells and the T-cells. This brings the cells close together so that the T-cells can kill the cancer cells. Catumaxomab also attaches to and activates Fc-gamma receptor positive immune cells like e.g. monocytes and macrophages, which also helps the body’s immune system to not only attack and destroy cancer cells, but also potentially induce a vaccination effect.
Under the terms of the multi-year commercial manufacturing agreement, Celonic Group will leverage its expertise in GMP manufacturing to produce catumaxomab at its state-of-the-art manufacturing facility in Heidelberg, Germany.
About LINDIS Biotech and Celonic
LINDIS Biotech is a bio-pharmaceutical company that is committed to the development of Triomab® antibodies – a new class of T-cell engaging bispecific trifunctional antibodies, empowering the immune system to turn malignant cancers into manageable and possibly curable diseases.
Celonic (Germany) is a Biologics Contract Development Manufacturing Organization (CDMO) with significant expertise in cell culture technologies, process development and manufacturing of recombinant proteins. Its headquarters is in Basel, Switzerland and its clinical and commercial GMP manufacturing facilities are in Heidelberg, Germany.